阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

已收盘 05-08 16:00:00 EDT

67.30

-2.77

-3.95%

盘后67.31

+0.01+0.01%

19:53 EDT

最高68.51	最低67.26	成交量714.59万
今开68.43	昨收70.07	日振幅1.78%
总市值2,087亿	流通市值2,079亿	总股本31.01亿
成交额4.83亿	换手率0.23%	流通股本30.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":67.3,"timestamp":1746734400000,"preClose":70.07,"halted":0,"volume":7145928,"hourTrading":{"tag":"盘后","latestPrice":67.31,"preClose":67.3,"latestTime":"19:53 EDT","volume":394486,"amount":26548982.1503,"timestamp":1746748421733},"delay":0,"floatShares":3089223171,"shares":3101276904,"eps":2.484749,"marketStatus":"已收盘","change":-2.77,"latestTime":"05-08 16:00:00 EDT","open":68.43,"high":68.51,"low":67.26,"amount":483396232.39992,"amplitude":0.017839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.484749,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746777600000},"marketStatusCode":5,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":70.07,"dividendRate":0.023031,"preHourTrading":{"tag":"盘前","latestPrice":68.48,"preClose":70.07,"latestTime":"09:29 EDT","volume":112523,"amount":7698055.127909999,"timestamp":1746710999999},"postHourTrading":{"tag":"盘后","latestPrice":67.31,"preClose":67.3,"latestTime":"19:53 EDT","volume":394486,"amount":26548982.1503,"timestamp":1746748421733},"volumeRatio":1.547245,"optionData":{"bulkOrders":[{"symbol":"AZN","call":true,"expireDate":1747368000000,"strike":"73.0","timestamp":1746727419642,"price":0.1,"volume":6000,"amount":60000,"type":"-"},{"symbol":"AZN","call":false,"expireDate":1747368000000,"strike":"67.0","timestamp":1746730771492,"price":1.2,"volume":3000,"amount":360000,"type":"+"}]},"impliedVol":0.3476,"impliedVolPercentile":0.928},"requestUrl":"/m/hq/s/AZN/tweets","defaultTab":"tweets","newsList":[{"id":"2534118844","title":"阿斯利康5月8日成交额为4.83亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534118844","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534118844?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:16","pubTimestamp":1746753419,"startTime":"0","endTime":"0","summary":"美东时间2025年5月8日，阿斯利康成交额为4.83亿美元，成交额较昨日增加70.43%，当日成交量为714.59万股。阿斯利康于2025年5月8日跌3.95%，报67.3美元，该股过去5个交易日跌4.55%，年初至今涨4.39%，过去60日跌6.11%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-08|4.83亿|70.43%|714.59万|#|2025-05-07|2.83亿|-16.66%|404.00万|#|2025-05-06|3.40亿|54.27%|480.22万|#|2025-05-05|2.20亿|-43.09%|305.57万|#|2025-05-02|3.87亿|-5.31%|537.45万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091705a4776d6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509091705a4776d6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","BK4585","LU0889565916.HKD","BK4568","AZN","LU2456880835.USD","LU0109394709.USD","BK4588","BK4007","LU2462157665.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2533131009","title":"新事 | 罗氏、阿斯利康在中国又有大动作","url":"https://stock-news.laohu8.com/highlight/detail?id=2533131009","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533131009?lang=zh_cn&edition=full","pubTime":"2025-05-08 22:11","pubTimestamp":1746713495,"startTime":"0","endTime":"0","summary":"5月8日，罗氏制药中国宣布投资20.4亿元，用于在上海新建生物制药生产基地。本次投资用于法瑞西单抗注射液的本地化生产 ，不断满足中国患者对于创新疗法需求。这个投资项目位于张江高科技园区，建筑面积约2.5万平方米，是罗氏制药在中国的第二个创新药物生产基地。待建成之后，将与百米之外的罗氏制药中国区总部现有生产基地协同运作。同样在5月8日，阿斯利康无锡小分子药物新工厂项目开工。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508222524a6d7d211&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508222524a6d7d211&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0320765992.SGD","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","AZN","BK4588","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","BK4585","BK4007","LU2456880835.USD"],"gpt_icon":0},{"id":"2533357341","title":"阿斯利康盘中异动 快速下挫3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533357341","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533357341?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:35","pubTimestamp":1746711330,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日21时35分，阿斯利康股票出现波动，股价大幅下挫3.05%。截至发稿，该股报67.94美元/股，成交量48.6361万股，换手率0.02%，振幅0.69%。阿斯利康股票所在的制药行业中，整体跌幅为1.50%。消息层面，截至21时35分，《安序源科技赴港IPO：连续两年亏损，阿斯利康中金、云锋基金等参投》资讯为影响阿斯利康的重要信息。根据招股书，安序源科技于2023年、2024年分别亏损2285.6万美元和2346.6万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508213530aa2c8729&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508213530aa2c8729&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4007","BK4588","BK4585","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","LU0889565916.HKD","AZN","LU2456880835.USD","LU0109394709.USD","BK4568","LU0320765992.SGD"],"gpt_icon":0},{"id":"2534633341","title":"阿斯利康退出CNS，释放的两个信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2534633341","media":"医药时间","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534633341?lang=zh_cn&edition=full","pubTime":"2025-05-08 20:23","pubTimestamp":1746707029,"startTime":"0","endTime":"0","summary":"2016年底，礼来与阿斯利康达成合作协议，共同开发MEDI1814，为此礼来支付了3000万美元的预付款。团队解散与裁员紧随其后，在一季度财报电话会议上，阿斯利康宣布全面退出神经科学领域。阿尔兹海默症也有所突破，FDA批准donanemab用于治疗早期阿尔茨海默病的成年患者。对于阿斯利康来说，专利悬崖近在咫尺，必须做出改变。阿斯利康强调，这一战略调整将“确保资源投向能够带来长期价值的项目”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509030710a6d80d91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509030710a6d80d91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4007","BK4588","BK4585","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","CNS","BK4135","AZN","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","BK4568","LU0320765992.SGD"],"gpt_icon":0},{"id":"2533205904","title":"总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2533205904","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533205904?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:16","pubTimestamp":1746699401,"startTime":"0","endTime":"0","summary":"【总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工】5月8日，阿斯利康无锡小分子药物新工厂正式开工。新工厂总投资达4.75亿美元，占地约3万平方米，将装备两套前沿的片剂连续制造工艺设备和七条可持续药品包装生产线，主要生产阿斯利康在研管线中的心血管创新药，预计于2028年第四季度投产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505083399599067.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505083399599067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4568","LU0320765992.SGD","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","AZN","BK4588","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","BK4585","BK4007","LU2456880835.USD"],"gpt_icon":0},{"id":"2533909490","title":"总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2533909490","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533909490?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:13","pubTimestamp":1746699211,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0109394709.USD","LU2417539215.USD","BK4568","06978","BK4588","LU2456880835.USD","LU1829250122.USD","BK1161","BK4585","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","159992","LU0889565916.HKD","BK1574"],"gpt_icon":0},{"id":"2533962879","title":"安序源科技赴港IPO：连续两年亏损，阿斯利康中金、云锋基金等参投","url":"https://stock-news.laohu8.com/highlight/detail?id=2533962879","media":"面包财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533962879?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:38","pubTimestamp":1746596280,"startTime":"0","endTime":"0","summary":"4月30日，安序源科技Axbio International Limited（以下简称 “安序源科技\"）在港交所递交招股书，拟香港主板挂牌上市，中金公司和浦银国际担任联席保荐人。安序源科技是一家集成电路生物科技企业。据招股书显示，安序源科技最近两年来连续亏损，且尚未从在研产品的商业销售中产生收入。集成电路生物科技企业 连续两年亏损安序源科技成立于2016年，主要产品包括分子诊断产品、用于多组学分析","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050713390594eeda1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050713390594eeda1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU1829250122.USD","LU0889565916.HKD","LU2456880835.USD","LU2462157665.USD","LU0320765992.SGD","BK4568","BK4585","BK4588","LU2417539215.USD","LU2236285917.USD","BK4007","AZN"],"gpt_icon":0},{"id":"2533195256","title":"阿斯利康5月6日成交额为3.40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533195256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533195256?lang=zh_cn&edition=full","pubTime":"2025-05-07 09:17","pubTimestamp":1746580625,"startTime":"0","endTime":"0","summary":"美东时间2025年5月6日，阿斯利康成交额为3.40亿美元，成交额较昨日增加54.27%，当日成交量为480.22万股。阿斯利康于2025年5月6日跌2.54%，报70.26美元，该股过去5个交易日跌2.02%，年初至今涨8.98%，过去60日跌0.96%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-06|3.40亿|54.27%|480.22万|#|2025-05-05|2.20亿|-43.09%|305.57万|#|2025-05-02|3.87亿|-5.31%|537.45万|#|2025-05-01|4.09亿|40.45%|582.01万|#|2025-04-30|2.91亿|-48.32%|405.73万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507091726a6d5a943&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507091726a6d5a943&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU2236285917.USD","LU2462157665.USD","BK4588","AZN","LU0320765992.SGD","BK4007","LU1829250122.USD","LU2456880835.USD","BK4568","BK4585","LU0109394709.USD","LU2417539215.USD"],"gpt_icon":0},{"id":"2533667622","title":"太平洋医药日报：阿斯利康BREZTRI三期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2533667622","media":"太平洋证券股份...","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533667622?lang=zh_cn&edition=full","pubTime":"2025-05-07 00:00","pubTimestamp":1746547200,"startTime":"0","endTime":"0","summary":"行业要闻：近日，阿斯利康宣布，三联吸入气雾剂Breztri在哮喘控制不佳患者中进行的两项3期临床试验KALOS 和LOGOS 中获得积极顶线结果。Breztri 是一种吸入式三联组合疗法，目前已在包括美国、欧盟、中国和日本在内的全球80 多个国家和地区获批用于治疗成人慢性阻塞性肺病。众生药业：公司发布公告，子公司众生睿创自主研发的RAY1225 注射液于近日获得减重和降糖两项II 期临床试验剂量扩展组的顶线分析数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505071504509751a0e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","LU0320765992.SGD","AZN","LU1829250122.USD","LU0109394709.USD","BK4588","LU2417539215.USD","BK4007","BK4568"],"gpt_icon":0},{"id":"2533590416","title":"阿斯利康(AZN)BTK抑制剂新适应症获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533590416","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533590416?lang=zh_cn&edition=full","pubTime":"2025-05-06 23:20","pubTimestamp":1746544807,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZGFjNmMxNjJiOWZlZTExMTI2OTIxOTcyMDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"288224","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AZN","LU2456880835.USD","LU2236285917.USD","BK4568","LU0889565916.HKD","LU0109394709.USD","BK4007","LU0320765992.SGD","LU2462157665.USD","LU2417539215.USD","BK4585","LU1829250122.USD"],"gpt_icon":0},{"id":"2533635563","title":"金十数据整理：每日美股市场要闻速递（5月6日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2533635563","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533635563?lang=zh_cn&edition=full","pubTime":"2025-05-06 20:49","pubTimestamp":1746535743,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVDU","NVDX","PONY","USJW.SI","GOOG","3NVD.UK","2NVD.UK","AZN","LU0640476718.USD","NVDL","ORCL","TSYW.SI","LU2360032135.SGD","LU1430594728.SGD","LU1235294995.USD","FXE","GOOGL","MEURmain","NVD","LU1585245621.USD","IE00BJTD4V19.USD","UBER","DASH","NVDA","NVD3.UK","EUO","LU0353189680.USD","LU1244550577.SGD","LU0980610538.SGD","YINN","TSLA","NVDD","TSLL","LU0061474960.USD","SGXZ31699556.SGD","NVDY","NVD2.UK","LU1852331112.SGD","SNVD.UK","HK0000320264.USD","IE00B3M56506.USD","NVDS","IE00BJTD4N35.SGD","LU1035775433.USD","EURmain","IBM","LU0149725797.USD","NVDS.UK","01163","NVIW.SI"],"gpt_icon":0},{"id":"2533752907","title":"阿斯利康(AZN.US)BTK抑制剂新适应症获欧盟批准 用于治疗套细胞淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2533752907","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533752907?lang=zh_cn&edition=full","pubTime":"2025-05-06 14:52","pubTimestamp":1746514320,"startTime":"0","endTime":"0","summary":"当地时间5月6日，阿斯利康宣布，阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准，用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤成年患者。新闻稿指出，这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。接受阿可替尼联合治疗的患者的中位无进展生存期  为 66.4 个月， 而单独接受化疗免疫疗法的患者的中位 PFS 为 49.6 个月。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrenz0681593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","LU2462157665.USD","BK4568","AZN","LU2456880835.USD","LU2236285917.USD","BK4588","LU0320765992.SGD","LU2417539215.USD","BK4007","LU1829250122.USD","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2533378157","title":"阿斯利康全面退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2533378157","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533378157?lang=zh_cn&edition=full","pubTime":"2025-05-05 08:43","pubTimestamp":1746405780,"startTime":"0","endTime":"0","summary":"阿斯利康宣布全面退出神经科学领域，终止多个研发项目，因研发难度大、市场竞争激烈且财务贡献微薄，未来将转向减重、免疫学等核心领域发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250505101109974f3f86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250505101109974f3f86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2417539215.USD","BK4585","LU0889565916.HKD","BK4568","BK4007","LU0320765992.SGD","LU2456880835.USD","AZN","BK4588","LU2236285917.USD","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2532548355","title":"阿斯利康2025财年第一财季实现净利润29.16亿美元，同比增加33.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532548355","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532548355?lang=zh_cn&edition=full","pubTime":"2025-05-04 00:00","pubTimestamp":1746288044,"startTime":"0","endTime":"0","summary":"5月4日，阿斯利康公布财报，公告显示公司2025财年第一财季净利润为29.16亿美元，同比增加33.82%；其中营业收入为135.88亿美元，同比增加7.17%，每股基本收益为0.94美元。从资产负债表来看，阿斯利康总负债651.22亿美元，其中短期债务37.58亿美元，资产负债比为0.01，流动比率为0.90。机构评级：截至2025年5月4日，当前有25家机构对阿斯利康目标价做出预测，其中目标均价为92.10美元，其中最低目标价为72.97美元，最高目标价为116.49美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504000057a6d22612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504000057a6d22612&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN"],"gpt_icon":0},{"id":"2532987962","title":"阿斯利康盘中异动 下午盘股价大涨3.01%报72.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532987962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532987962?lang=zh_cn&edition=full","pubTime":"2025-05-03 03:23","pubTimestamp":1746213804,"startTime":"0","endTime":"0","summary":"北京时间2025年05月03日03时23分，阿斯利康股票出现异动，股价急速上涨3.01%。截至发稿，该股报72.63美元/股，成交量388.487万股，换手率0.13%，振幅1.82%。阿斯利康股票所在的制药行业中，整体涨幅为3.24%。该信息摘要如下：4月29日，阿斯利康发布2025年第一季度财报，公司在报告期内实现营收135.88亿美元，同比增长10%。意见书显示，阿斯利康涉嫌偷逃进口税款，金额超160万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503032324974d920f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503032324974d920f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","BK4568","LU2456880835.USD","BK4588","AZN","LU0320765992.SGD","LU1829250122.USD","BK4585","LU2462157665.USD","LU0109394709.USD","LU2236285917.USD","BK4007","LU0889565916.HKD"],"gpt_icon":0},{"id":"2532886623","title":"速递｜砍掉神经管线，阿斯利康彻底转向专注于减肥与免疫赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2532886623","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532886623?lang=zh_cn&edition=full","pubTime":"2025-05-02 11:44","pubTimestamp":1746157479,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队2025年4月29日，阿斯利康在发布2025年第一季度财报时宣布，将正式退出神经科学领域的研发工作，未来将更加专注于减重、免疫学等核心治疗方向。目前，阿斯利康在神经科学方向已无在研项目。目前，阿斯利康正在加快推进包括口服GLP-1药物和乳腺癌候选药物camizestrant在内的多个关键项目。此类策略有望缓解GLP-1类药物导致的肌肉流失问题，并进一步拓展治疗适应范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502121759a46f9a32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502121759a46f9a32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4568","BK4585","LU1829250122.USD","LU2462157665.USD","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD","AZN","LU0889565916.HKD","LU2456880835.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2532385934","title":"阿斯利康5月1日成交额为4.09亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532385934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532385934?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:17","pubTimestamp":1746148629,"startTime":"0","endTime":"0","summary":"美东时间2025年5月1日，阿斯利康成交额为4.09亿美元，成交额较昨日增加40.45%，当日成交量为582.01万股。阿斯利康于2025年5月1日跌1.78%，报70.51美元，该股过去5个交易日涨1.38%，年初至今涨9.37%，过去60日涨3.83%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-01|4.09亿|40.45%|582.01万|#|2025-04-30|2.91亿|-48.32%|405.73万|#|2025-04-29|5.64亿|0.18%|791.91万|#|2025-04-28|5.63亿|21.81%|802.34万|#|2025-04-25|4.62亿|94.02%|666.27万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502091717a46f7946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502091717a46f7946&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2417539215.USD","BK4568","LU2456880835.USD","LU1829250122.USD","BK4585","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2532012916","title":"阿斯利康4月30日成交额为2.91亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532012916","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532012916?lang=zh_cn&edition=full","pubTime":"2025-05-01 09:17","pubTimestamp":1746062226,"startTime":"0","endTime":"0","summary":"美东时间2025年4月30日，阿斯利康成交额为2.91亿美元，成交额较昨日减少48.32%，当日成交量为405.73万股。阿斯利康于2025年4月30日涨0.11%，报71.79美元，该股过去5个交易日涨4.79%，年初至今涨11.35%，过去60日涨4.33%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-30|2.91亿|-48.32%|405.73万|#|2025-04-29|5.64亿|0.18%|791.91万|#|2025-04-28|5.63亿|21.81%|802.34万|#|2025-04-25|4.62亿|94.02%|666.27万|#|2025-04-24|2.38亿|-38.92%|343.21万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501091712a6cf83bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501091712a6cf83bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","BK4588","LU0320765992.SGD","LU1829250122.USD","BK4007","BK4585","LU2417539215.USD","LU2462157665.USD","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2531703130","title":"阿斯利康涉嫌未缴纳进口税，在华或面临800万美元新罚款，一季度中国市场业绩增长小于整体新兴市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2531703130","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531703130?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:24","pubTimestamp":1745997883,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月30日讯 阿斯利康可能会在中国面临一项新的罚款，金额或达800万美元。英国当地时间4月29日，阿斯利康公布2025年一季报，其中单独对中国市场“2025年4月，与中国调查有关的事态发展”做出了详细描述。意见书显示阿斯利康涉嫌偷逃进口税款，金额达160余万美元。若阿斯利康被最终判定需承担法律责任，可能被处以未缴进口税款一至五倍的罚金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/256427","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["YINN","AZN","BK4007","BK4568","LU1829250122.USD","LU0889565916.HKD","LU2456880835.USD","LU2417539215.USD","LU2462157665.USD","LU0109394709.USD","BK4614","LU0320765992.SGD","BK4585","LU2236285917.USD","BK4588"],"gpt_icon":0},{"id":"2531770654","title":"【洞察】达格列净二甲双胍缓释片属于口服降糖复方制剂 我国市场竞争在不断加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2531770654","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531770654?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:22","pubTimestamp":1745994136,"startTime":"0","endTime":"0","summary":"达格列净二甲双胍缓释片是一种新型口服降糖复方制剂，结合了达格列净及盐酸二甲双胍缓释片两种药物作用机制。达格列净二甲双胍缓释片适用于2型糖尿病的治疗。复方制剂是口服降糖药市场新风口，近年来，我国市场规模逐年增长，达格列净二甲双胍缓释片作为新型口服降糖复方制剂，市场发展前景好。目前达格列净二甲双胍缓释片市场已吸引一大批企业布局，未来国产仿制药将逐渐侵蚀进口原研药市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142221974b299c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4007","LU2456880835.USD","LU2236285917.USD","LU0889565916.HKD","LU2462157665.USD","BK4585","LU0320765992.SGD","BK4588","LU2417539215.USD","BK4568","LU1829250122.USD","AZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":0.0651},{"period":"3month","weight":-0.0316},{"period":"6month","weight":0.0865},{"period":"1year","weight":-0.0819},{"period":"ytd","weight":0.0694}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.1126},{"period":"3month","weight":-0.0745},{"period":"6month","weight":-0.0619},{"period":"1year","weight":0.0851},{"period":"ytd","weight":-0.0425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.5,"avgChangeRate":0.00755},{"month":6,"riseRate":0.46875,"avgChangeRate":0.020173},{"month":7,"riseRate":0.59375,"avgChangeRate":-0.004027},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.000033},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007964}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}